Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADA | P00813 | 1/20 | 0.54 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582394 | 1.00 | AHCY (0.60) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22992329 | 1.00 | AHCY (0.60) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31309583 | 1.00 | AHCY (0.60) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22762138 | 1.00 | AHCY (0.60) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| Magnesium SCHEMBL31309216 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31309711 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31309571 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| Calcium SCHEMBL31309558 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| Ammonia Solution, Strong SCHEMBL31309620 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB | |
| Potassium SCHEMBL31309656 | 0.99 | AHCY (0.59) | AHCYPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522932-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-12-20 | — | — | US | disclosed |
| US-9249177-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-02-02 | — | — | US | disclosed |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2016-01-14 | — | — | US | disclosed |
| EP-1720890-B1 | PHOSPONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | LEUVEN K U RES & DEV (BE) | 2015-05-20 | — | — | EP | disclosed |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809520-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-08-19 | — | — | US | disclosed |
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2014-02-06 | — | — | US | disclosed |
| US-8501709-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-05-03 | — | — | US | disclosed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039179-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | AHCY 1632/4885PI4KA 309/4885PI4K2B 298/4885 |
| US-20120108531-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | TYMP, PNP, NUDT1 | AHCY 945/4885PI4KA 76/4885PI4K2B 119/4885 |
| US-20070185062-A1 | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | ENTPD5, PPA1, TYMP | AHCY 2136/4885PI4KA 72/4885PI4K2B 118/4885 |
| US-20160009750-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | AHCY 1632/4885PI4KA 309/4885PI4K2B 298/4885 |
| US-20140316127-A1 | PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION | PNP, NUDT1, TYMP | AHCY 1632/4885PI4KA 309/4885PI4K2B 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.